An Open-label, Non-randomized, Pharmacokinetic and Safety Study of Single Dose GSK573719 + GW643444 (VI) Combination and Repeat Doses of GSK573719 in Healthy Subjects and in Subjects With Moderate Hepatic Impairment

Trial Profile

An Open-label, Non-randomized, Pharmacokinetic and Safety Study of Single Dose GSK573719 + GW643444 (VI) Combination and Repeat Doses of GSK573719 in Healthy Subjects and in Subjects With Moderate Hepatic Impairment

Completed
Phase of Trial: Phase I

Latest Information Update: 27 Jul 2017

At a glance

  • Drugs Umeclidinium (Primary) ; Umeclidinium/vilanterol (Primary)
  • Indications Chronic obstructive pulmonary disease
  • Focus Pharmacokinetics
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 11 Sep 2013 Results presented at the 23rd Annual Congress of the European Respiratory Society.
    • 14 Jun 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 01 Jun 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top